Formulations of hormone therapy and risk of Parkinson's disease.
Identifieur interne : 000381 ( PubMed/Corpus ); précédent : 000380; suivant : 000382Formulations of hormone therapy and risk of Parkinson's disease.
Auteurs : Jessica I. Lundin ; Thanh G N. Ton ; Andrea Z. Lacroix ; W T Longstreth ; Gary M. Franklin ; Phillip D. Swanson ; Terri Smith-Weller ; Brad A. Racette ; Harvey CheckowaySource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Estrogens, Esterified (USP), Progestins.
- adverse effects : Estrogen Replacement Therapy.
- etiology : Parkinson Disease.
- chemical , therapeutic use : Estrogens, Esterified (USP).
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Middle Aged.
Abstract
Hormone therapy (HT) is a class of medications widely prescribed to women in the Western world. Evidence from animal models and in vitro studies suggests that estrogen may protect against nigrostriatal system injury and increase dopamine synthesis, metabolism, and transport. Existing epidemiologic research indicates a possible reduced risk of Parkinson's disease (PD) associated with HT use. The objective of this study was to evaluate PD risk associated with specific HT formulations. Neurologist-confirmed cases and age-matched controls were identified from Group Health Cooperative (GHC) of Washington State. Final analysis included 137 female cases and 227 controls. Hormone therapy use was ascertained from the GHC pharmacy database, further classified as conjugated estrogens, esterified estrogens, and progestin. Ever use of HT formulation demonstrated a suggested elevated risk with esterified estrogen use (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.0-9.8), and no risk associated with conjugated estrogen use (OR, 0.6; 95% CI, 0.6-1.3). Restricting this analysis to prescriptions that included progestin further elevated the risk associated with esterified estrogen use (OR, 6.9; 95% CI, 2.1-22.9); again, no risk was associated with conjugated estrogen use (OR, 1.7; 95% CI, 0.6-5.0). The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These findings could have important implications for choice of HT in clinical practice.
DOI: 10.1002/mds.26037
PubMed: 25255692
Links to Exploration step
pubmed:25255692Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Formulations of hormone therapy and risk of Parkinson's disease.</title><author><name sortKey="Lundin, Jessica I" sort="Lundin, Jessica I" uniqKey="Lundin J" first="Jessica I" last="Lundin">Jessica I. Lundin</name><affiliation><nlm:affiliation>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ton, Thanh G N" sort="Ton, Thanh G N" uniqKey="Ton T" first="Thanh G N" last="Ton">Thanh G N. Ton</name></author><author><name sortKey="Lacroix, Andrea Z" sort="Lacroix, Andrea Z" uniqKey="Lacroix A" first="Andrea Z" last="Lacroix">Andrea Z. Lacroix</name></author><author><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W T" last="Longstreth">W T Longstreth</name></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M" last="Franklin">Gary M. Franklin</name></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D" last="Swanson">Phillip D. Swanson</name></author><author><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name></author><author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25255692</idno><idno type="pmid">25255692</idno><idno type="doi">10.1002/mds.26037</idno><idno type="wicri:Area/PubMed/Corpus">000381</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Formulations of hormone therapy and risk of Parkinson's disease.</title><author><name sortKey="Lundin, Jessica I" sort="Lundin, Jessica I" uniqKey="Lundin J" first="Jessica I" last="Lundin">Jessica I. Lundin</name><affiliation><nlm:affiliation>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ton, Thanh G N" sort="Ton, Thanh G N" uniqKey="Ton T" first="Thanh G N" last="Ton">Thanh G N. Ton</name></author><author><name sortKey="Lacroix, Andrea Z" sort="Lacroix, Andrea Z" uniqKey="Lacroix A" first="Andrea Z" last="Lacroix">Andrea Z. Lacroix</name></author><author><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W T" last="Longstreth">W T Longstreth</name></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M" last="Franklin">Gary M. Franklin</name></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D" last="Swanson">Phillip D. Swanson</name></author><author><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name></author><author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Estrogen Replacement Therapy (adverse effects)</term><term>Estrogens, Esterified (USP) (adverse effects)</term><term>Estrogens, Esterified (USP) (therapeutic use)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Parkinson Disease (etiology)</term><term>Progestins (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Estrogens, Esterified (USP)</term><term>Progestins</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Estrogen Replacement Therapy</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Estrogens, Esterified (USP)</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hormone therapy (HT) is a class of medications widely prescribed to women in the Western world. Evidence from animal models and in vitro studies suggests that estrogen may protect against nigrostriatal system injury and increase dopamine synthesis, metabolism, and transport. Existing epidemiologic research indicates a possible reduced risk of Parkinson's disease (PD) associated with HT use. The objective of this study was to evaluate PD risk associated with specific HT formulations. Neurologist-confirmed cases and age-matched controls were identified from Group Health Cooperative (GHC) of Washington State. Final analysis included 137 female cases and 227 controls. Hormone therapy use was ascertained from the GHC pharmacy database, further classified as conjugated estrogens, esterified estrogens, and progestin. Ever use of HT formulation demonstrated a suggested elevated risk with esterified estrogen use (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.0-9.8), and no risk associated with conjugated estrogen use (OR, 0.6; 95% CI, 0.6-1.3). Restricting this analysis to prescriptions that included progestin further elevated the risk associated with esterified estrogen use (OR, 6.9; 95% CI, 2.1-22.9); again, no risk was associated with conjugated estrogen use (OR, 1.7; 95% CI, 0.6-5.0). The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These findings could have important implications for choice of HT in clinical practice.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25255692</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>01</Day></DateCreated><DateCompleted><Year>2015</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>13</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Formulations of hormone therapy and risk of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>1631-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26037</ELocationID><Abstract><AbstractText>Hormone therapy (HT) is a class of medications widely prescribed to women in the Western world. Evidence from animal models and in vitro studies suggests that estrogen may protect against nigrostriatal system injury and increase dopamine synthesis, metabolism, and transport. Existing epidemiologic research indicates a possible reduced risk of Parkinson's disease (PD) associated with HT use. The objective of this study was to evaluate PD risk associated with specific HT formulations. Neurologist-confirmed cases and age-matched controls were identified from Group Health Cooperative (GHC) of Washington State. Final analysis included 137 female cases and 227 controls. Hormone therapy use was ascertained from the GHC pharmacy database, further classified as conjugated estrogens, esterified estrogens, and progestin. Ever use of HT formulation demonstrated a suggested elevated risk with esterified estrogen use (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.0-9.8), and no risk associated with conjugated estrogen use (OR, 0.6; 95% CI, 0.6-1.3). Restricting this analysis to prescriptions that included progestin further elevated the risk associated with esterified estrogen use (OR, 6.9; 95% CI, 2.1-22.9); again, no risk was associated with conjugated estrogen use (OR, 1.7; 95% CI, 0.6-5.0). The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These findings could have important implications for choice of HT in clinical practice.</AbstractText><CopyrightInformation>© 2014 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lundin</LastName><ForeName>Jessica I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ton</LastName><ForeName>Thanh G N</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>LaCroix</LastName><ForeName>Andrea Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Longstreth</LastName><ForeName>W T</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>Gary M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>Phillip D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Smith-Weller</LastName><ForeName>Terri</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Racette</LastName><ForeName>Brad A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Checkoway</LastName><ForeName>Harvey</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 ES017765</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24ES17765</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P42 ES004696</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P42ES004696</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES010750</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01ES010750</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042724">Estrogens, Esterified (USP)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011372">Progestins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Jul 15;24(9):1359-65</RefSource><PMID Version="1">19424986</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2000 May 24-31;283(20):2674-9</RefSource><PMID Version="1">10819950</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuroendocrinol. 2012 Jan;24(1):48-61</RefSource><PMID Version="1">21790809</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 2012 Sep 27;526(2):133-7</RefSource><PMID Version="1">22922325</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 Apr;19(4):457-60</RefSource><PMID Version="1">23402992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Neurosci. 2013 Oct;123(10):741-2</RefSource><PMID Version="1">23627690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2014 Sep;259:44-56</RefSource><PMID Version="1">24681088</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Jun 27;54(12):2292-8</RefSource><PMID Version="1">10881255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Neurobiol. 2001 Jan;63(1):29-60</RefSource><PMID Version="1">11040417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Nov 14;55(9):1358-63</RefSource><PMID Version="1">11087781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 2001 Aug;41(2):131-8</RefSource><PMID Version="1">11400179</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2001 Jul;50(1):56-63</RefSource><PMID Version="1">11456310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Aug 14;57(3):462-7</RefSource><PMID Version="1">11502914</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 Sep;16(5):830-7</RefSource><PMID Version="1">11746612</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res Bull. 1990 Aug;25(2):221-7</RefSource><PMID Version="1">2224537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1993 May;60(5):1876-83</RefSource><PMID Version="1">8473903</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 1997 Jun 23;157(12):1330-6</RefSource><PMID Version="1">9201007</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1997 Aug 1;764(1-2):9-16</RefSource><PMID Version="1">9295188</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1998 Apr;50(4):1141-3</RefSource><PMID Version="1">9566410</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 1998 May 30;844:153-65</RefSource><PMID Version="1">9668673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharmacol. 1999 Jul;56(1):31-8</RefSource><PMID Version="1">10385681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1999 Jul 13;53(1):91-5</RefSource><PMID Version="1">10408542</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuroendocrinol. 2005 Aug;17(8):509-17</RefSource><PMID Version="1">16011487</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2005 Jun;1052:145-51</RefSource><PMID Version="1">16024757</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 Aug 9;65(3):383-90</RefSource><PMID Version="1">16087902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2005 Dec;14(12):877-84</RefSource><PMID Version="1">15931653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Jul;21(7):964-9</RefSource><PMID Version="1">16550541</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Neuroendocrinol. 2008 Oct;29(4):507-19</RefSource><PMID Version="1">18522863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Endocrinol. 2008 Dec 16;296(1-2):87-93</RefSource><PMID Version="1">18755240</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2009 Jun;217(2):434-9</RefSource><PMID Version="1">19289119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocrinology. 2002 Jan;143(1):205-12</RefSource><PMID Version="1">11751611</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Epidemiol. 2002 Jan;55(1):25-31</RefSource><PMID Version="1">11781119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2002 Apr 15;155(8):732-8</RefSource><PMID Version="1">11943691</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2002 Jul 17;288(3):321-33</RefSource><PMID Version="1">12117397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2002 Sep;52(3):276-84</RefSource><PMID Version="1">12205639</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Mar 11;60(5):790-5</RefSource><PMID Version="1">12629235</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2003 Jun 1;157(11):1015-22</RefSource><PMID Version="1">12777365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):473-82</RefSource><PMID Version="1">12943738</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2004 Jun 8;62(11):2010-4</RefSource><PMID Version="1">15184606</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2004 Jun;61(6):886-8</RefSource><PMID Version="1">15210525</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2004 Oct 6;292(13):1581-7</RefSource><PMID Version="1">15467060</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1980 Jun 27;208(4451):1466-8</RefSource><PMID Version="1">7189902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 1985 Nov 5;117(2):197-203</RefSource><PMID Version="1">4076343</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 1990;5(2):157-64</RefSource><PMID Version="1">2309159</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):347-58</RefSource><PMID Version="1">10817919</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Menopause. 2010 May-Jun;17(3):622-9</RefSource><PMID Version="1">20215977</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015914">Estrogen Replacement Therapy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D042724">Estrogens, Esterified (USP)</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011372">Progestins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS628374</OtherID><OtherID Source="NLM">PMC4216612</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">estrogen therapy</Keyword><Keyword MajorTopicYN="N">hormone therapy</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25255692</ArticleId><ArticleId IdType="doi">10.1002/mds.26037</ArticleId><ArticleId IdType="pmc">PMC4216612</ArticleId><ArticleId IdType="mid">NIHMS628374</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000381 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000381 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25255692
|texte= Formulations of hormone therapy and risk of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25255692" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |